The global high-throughput screening market size is projected to reach USD 26.4 billion by 2025 from USD 15.3 billion in 2020, at a CAGR of 11.5%

ReportLinker
·4 min read

during the forecast period. The growth in this market is primarily attributed to increasing R&D spending by pharmaceutical & biotechnology companies, technological advancements in high-throughput screening market and the availability of government funding & venture capital investments.

New York, March 08, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "High-Throughput Screening Market by Product, Technology, Application, End User - Global Forecast to 2025" - https://www.reportlinker.com/p04405157/?utm_source=GNW
Emerging markets are expected to provide growth opportunities for players operating in the high-throughput screening market in the coming years. However, costly and time-consuming nature of HTS techniques and a serious shortage of skilled operators in the industry are the major challenge in this market.

The services segment accounted for the highest growth rate in the high-throughput screening market, by product & service, during the forecast period
The high-throughput screening market is segmented into consumables, instruments, , services, and software.The services segment accounted for the highest growth rate in the high-throughput screening market in 2020.

This segment’s large share can be attributed to large pharmaceutical companies routinely engaging in outsourcing many tasks such as screening and lead identification, toxicology, and other preclinical studies.

Contract research organizations segment accounted for the highest CAGR
Based on end user , the high-throughput screeningmarket is segmented into pharmaceutical & biotechnology companies, academic & research institutes, contract research organizations (CROs) and other end users.In 2020, contract research organizations accounted for the highest growth rate.

The major factor driving the growth of this segment is increasing trend of outsourcing of R&D activities by pharmaceutical and biotechnology companies.

Label-free Technology segment accounted for the highest CAGR
Based on technology , the high-throughput screeningmarket is segmented into cell-based assays, lab-on-a-chip technology, and label-free technology.In 2020, the label-free technology segment accounted for the highest growth rate.

Label-free technology provides a simple assessment technique for studying complex biological pathways as it does not involve the use of labels. This will support the growth of this technology segment in the HTS market during forecast period.

Drug Discovery segment accounted for the highest CAGR
Based on application , the high-throughput screeningmarket is segmented into drug discovery, biochemical screening, life sciences research and other applications.In 2020, the drug discovery segment accounted for the highest growth rate.

The key factor driving this segment’s growth is the increasing number of clinical trials and rising pharmaceutical R&D expenditure.

Asia Pacific: The fastest-growing country in the high-throughput screening market
The high-throughput screening market is segmented into North America, Europe, Asia Pacific, and the Rest of the World (RoW).Asia Pacific is projected to register the highest CAGR during the forecast period.

Factors such as the rising R&D spending, growing public-private partnerships, and increasing government funding are factors driving the growth of the HTS market in this region.

The primary interviews conducted for this report can be categorized as follows:
• By Company Type: Tier 1 - 37%, Tier 2 - 22%, and Tier 3 - 41%
• By Designation: C-level - 25%, D-level - 20%, and Others - 55%
• By Region: North America -40%, Europe -27%, Asia-Pacific -20%, RoW -13%

Lists of Companies Profiled in the Report:
• Thermo Fisher Scientific, Inc. (US)
• Agilent Technologies, Inc. (US)
• Merck KGaA (Germany)
• Danaher Corporation (US)
• PerkinElmer, Inc. (US)
• Tecan Group Ltd. (Switzerland)
• AXXAM S.p.A (Italy)
• Promega Corporation (US)
• Bio-Rad Laboratories, Inc.(US)
• Promega Corporation (US)
• Hamilton Company (US)
• Corning Incorporated (US)
• Charles River Laboratories (US)
• Lonza (Switzerland)
• REPROCELL Inc. (Japan)
• Aurora Biomed (Canada)
• BMG LABTECH (Germany)
• DIANA Biotechnologies, s.r.o. (Czech Republic)
• NanoTemper Technologies GmbH (Germany)
• Creative Biolabs (US)
• Biomat Srl (Italy)

Research Coverage:
This report provides a detailed picture of the Immunofluorescence assay market.It aims at estimating the size and future growth potential of the market across different segments, such as the product, type, disease, end user, and region.

The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall high-throughput screening market and its subsegments.It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies.

This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, trends, opportunities, and challenges.

Read the full report: https://www.reportlinker.com/p04405157/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001